Novel and potent calcium-sensing receptor antagonists: Discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent

Add time:08/12/2019    Source:sciencedirect.com

The calcium-sensing receptor antagonist (CaSR) has been recognized as a promising target of anabolic agents for treating osteoporosis. In the course of developing a new drug candidate for osteoporosis, we found tetrahydropyrazolopyrimidine derivative 1 to be an orally active CaSR antagonist that stimulated transient PTH secretion in rats. However, compound 1 showed poor physical and chemical stability. In order to work out this compound’s chemical stability and further understand its in vivo efficacy, we focused on modifying the 2-position of the tetrahydropyrazolopyrimidine. As a result of chemical modification, we discovered (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate 10m (TAK-075), which showed improved solubility, chemical stability, and in vivo efficacy. Furthermore, we describe that evaluating the active metabolite is important during repeated treatment with short-acting CaSR antagonists.

We also recommend Trading Suppliers and Manufacturers of 2,3-BIS(4-ETHYLPHENYL)-5-PHENYLTETRAZOLIUM CHLORIDE (cas 104497-78-1). Pls Click Website Link as below: cas 104497-78-1 suppliers

Prev:Halofluorination of 1,2-difluoro-1,2-di(p-tolyl)ethene, 1,2,3,4-tetrafluoro-1,4-di(p-tolyl) butadiene and its nonfluorinated parent compounds
Next:Some results on modules satisfying S-strong accr∗)